item management s discussion and analysis of results of operations and of financial conditions general bard is a leading multinational developer  manufacturer and marketer of products for the large and growing health care industry 
worldwide health care expenditures approximated trillion in with about half that amount spent in the united states 
bard s segment of this industry  itself a multi billion dollar market  is primarily specialized products used mainly in hospitals  in outpatient centers and in physician s offices to meet the needs of the medical profession in caring for their patients 
the company seeks to focus and concentrate on selected diseases with cost effective  innovative products and specialized sales forces to maximize bard s opportunities in managing these diseases 
summary results consolidated net sales increased in growth was negatively affected by divested and de emphasized product lines  sales denominated in foreign currencies that weakened against the us dollar and a continued reduction in average selling prices 
net income and basic earnings per share in and were both affected by one time items 
in the major one time item was a million million after tax charge for the company s manufacturing restructuring plan 
the plan relates to activities which will be implemented during the next twenty one months and when completed are estimated to result in pretax cost savings of approximately million annually 
the company s current estimates show a savings of approximately cents per share in and approximately cents per share in the year and beyond 
please refer to page ii of this financial review for a summary of one time items affecting income in the last three years 
results of operations vs 
net sales rose to billion 
divested and de emphasized product lines reduced the growth in sales by 
price reductions totaled about and the stronger dollar reduced reported sales by 
excluding these items  sales would have grown approximately 
sales of vascular products rose in radiology devices showed strong growth  primarily in us markets 
a full year of sales of graft products from the acquisition of impra  inc in september added significantly to the growth rate of vascular products 
urology product sales grew in the infection control foley catheter and the contigen bard collagen implant provided the growth in this area 
ii results of operations vs 
continued sales of oncology products increased in specialty venous access devices showed good growth  particularly in international markets 
biopsy products had good growth in us markets 
sales of surgical specialty products grew in  propelled by high growth worldwide of mesh products used primarily for hernia repair 
the four product areas discussed above are bard s emphasis products which accounted for over of total sales in the combined growth of emphasis products was in and would have grown without the negative impact of foreign currencies 
other product group sales declined in  primarily as a result of the sale and discontinuance of several product lines 
net sales by product group for the last three years in millions are vascular urology oncology surgery total emphasis products    other net sales    sales in the united states rose in to million  representing of worldwide sales 
sales of emphasis products rose while the decline in de emphasized product resulted in the small overall increase in us sales 
vascular and surgical specialty product areas provided the best growth in the us sales outside the us increased in and would have grown without the effect of a reduction in foreign currency translation 
in local currency values  bard experienced solid sales gains in vascular grafts helped by the acquisition of impra in  specialty access devices  mesh products and basic urological drainage devices 
the geographic breakdown of sales outside the us for the last three years is europe  middle east  africa asia pacific area and western hemisphere  excluding us ii results of operations vs 
continued bard s cost of goods sold showed good improvement to of sales compared with in bard s efforts to reduce manufacturing costs and the acquisition of impra resulted in this improvement 
marketing  selling and administrative expenses increased almost in primarily due to a full year of spending associated with the impra acquisition and the costs associated with programming changes for the year these expenses grew faster than sales and were at a level of of sales in compared with in spending for research and development increased in to of sales from of sales in this increase in spending will help ensure that the company has the new products that are essential to bard s growth 
additional interest expense for the full year of related to acquisitions in primarily impra in september and resulted in the increase in total interest expense for the year 
costs of million in to combine the operations of acquisitions affected income in that year 
there were no such costs in please refer to note  other income expense  net of the notes of consolidated financial statements in this report for a summary of items in this category in the last three years 
included in this category in are charges of million for a manufacturing restructuring plan and million associated with the impairment of investments and intangible assets  and a legal settlement 
these charges were partially offset by gains of million on the sale of the surgical suction and irrigation product line and million from the sales of other product lines and assets 
income tax the effective tax rate was in  in and in the lower tax rate in was primarily due to the increased tax benefit in the us related to one time charges and the reversals of approximately million in tax reserves no longer required 
the tax benefit from operations in ireland and puerto rico favorably affected the tax rate in each year 
net income net income decreased to million in from million in this was due in large part to the million charge million after tax for a manufacturing restructuring plan 
the following chart shows the effect on net income and on basic and diluted earnings per share of one time items during the last three years 
ii net income continued manufacturing restructuring plan impairment of investments  intangible assets and legal settlement year costs sales of product lines and other assets total equivalent per share basic 
diluted 
reorganization  asset writedown and costs to combine operations reversal of tax reserves prior period royalty payments  legal settlement and other total equivalent per share basic 
diluted 
costs to combine operations equivalent per share basic 
diluted 
after adjusting for the items shown above  net income and earnings per share eps would have been net income basic diluted millions eps eps for information on the calculation of basic and diluted earnings per share  please refer to note of the notes to consolidated financial statements on page ii results of operations vs 
net sales totaled billion in  a increase over price reductions totaled about worldwide while a stronger dollar reduced reported sales by 
sales of vascular products rose in to million 
radiology devices showed strong growth 
sales of grafts increased sharply as a result of the september acquisition of impra and sales of cardiac assist devices acquired from st 
jude medical in january also added to the vascular growth rate 
ii results of operations vs 
continued urological product sales totaled million in  a increase over basic drainage products and specialty devices contributed to this growth 
the company s growth in urological products was significantly higher in the us than in international markets 
sales of oncological products grew to million in  primarily from a strong increase in the specialty venous access area 
surgical specialty products were up in to in sales 
mesh products  which are used primarily in hernia repair  showed a substantial gain in sales 
worldwide sales of the emphasis products described above grew in to billion and represented of bard s total sales 
other products are de emphasized and sales in this area declined by in to million 
sales in the united states grew in to million  representing of worldwide sales 
surgical specialties turned in the highest growth rate of the four emphasis product groups  but the urological area continues to generate the most revenue and also showed good growth 
the good increase in sales of oncological products came primarily from growth in specialty access and biopsy devices 
vascular sales showed improvement primarily as a result of the acquisition of impra 
sales of other  de emphasized products declined 
sales outside the us grew in to million  representing of worldwide sales  compared with in growth was highest in the oncological and surgical specialties areas 
sales of vascular products showed good increases from grafts and radiology devices  and were helped by strong balloon angioplasty sales in europe 
sales of urological products showed a small increase with gains primarily in basic drainage and continence products 
the effect of currency translation was to lower international sales by almost for the year 
excluding this effect  reported international sales would have increased over the prior year 
the cost of goods sold as a percent of sales was in and in the prior year as market price reductions exceeded the company s gains in manufacturing efficiencies and efforts to shift the mix to higher margin products 
marketing  selling and administrative expenses increased just over in  lower than the rate of growth in sales  as efforts were increased to lower expenses to help offset some of the effects of price declines 
also  bard realized synergies from the two mergers completed late in as a percent to total sales  these expenses represented in compared with in ii results of operations vs 
continued research and development spending increased over in  representing of sales  slightly less than the ratio to sales in in an effort to reduce costs  the company eliminated certain planned spending while continuing sufficient work on the programs needed for bard s future success 
additional interest expense related to acquisitions in resulted in an increase in total interest expense for the year 
costs to combine the operations of acquisitions of million in and million in affected income in both years 
other income expense  net  in included charges of million for the write down of assets related to guidewire technology  million for the closing of certain manufacturing operations and a net amount of million for certain legal fees and settlements 
also included are nonrecurring royalty payments of million received in for prior periods 
no nonrecurring items were recorded in this category in the effective income tax rate was in excluding the impact of the first quarter reversal of approximately million in tax reserves no longer required and the increased tax benefit in the us related to the one time charges discussed previously  the effective tax rate would have been compared with in net income increased in and in each year was affected by one time items as described earlier in this financial review 
year expenditures the company utilizes software and related technologies that will be affected by the date change in the year marketing  selling and administrative expense in includes million for year expenditures 
the company estimates the need for additional expenditures of million in  million in and million in financial condition and liquidity bard s financial condition remains strong 
total debt was reduced by million to at the end of and the ratio of total debt to total capitalization declined to from 
long term debt was million at december   including million of commercial paper borrowing that remains classified as long term with the backing of bard s committed credit facility 
the company has a million syndicated  committed credit facility with a group of banks 
the facility expires in june ii financial condition and liquidity the credit agreement supports a commercial paper program which started in september with a maximum amount of million  reduced to million effective january  the company borrows actively under this program 
in addition to the million committed credit agreement  bard maintains uncommitted credit lines with banks for short term cash needs and these lines were used as needed during the last three years 
at december   the unused uncommitted lines of credit totaled million 
as now structured  the company expects cash flow from operating activities to exceed capital expenditures and dividend payments 
the company believes it could borrow adequate funds at competitive terms and rates  should it be necessary 
this overall financial strength gives bard sufficient financing flexibility 
total cash outlays made for purchases of businesses  patents  trademarks and other related items were approximately million in  million in and million in for a total over the last three years of million 
the majority of these investments were for intangible assets  reflecting the premium over book value for these purchases 
the cash outlays exclude common stock valued at million issued in for the acquisitions of medchem products and american hydro surgical 
the majority of the cash outlays were financed with additional debt which increased a total of million during the three year period with the balance coming from cash from operations 
periodically  the company purchases its common stock in the open market 
total shares purchased were  in   in and  in in september the board of directors authorized the purchase from time to time of up to million shares of which  had been purchased as of december  foreign currency risk the company periodically enters into foreign exchange contracts to reduce its exposure to fluctuations in currency values 
contracts have been for the forward purchase of  and options in  currencies in which the company has known or anticipated payments 
these are primarily for intercompany transactions  resulting in a high degree of confidence that the anticipated transactions will take place 
monetary assets of the company held in foreign currencies have relatively short maturities and are denominated in currencies that have not experienced wide short term fluctuations in their equivalent us dollar values 
please refer to note of the notes to consolidated financial statements on page ii of this report for current details of the company s foreign exchange contracts 
ii legal proceedings for a discussion of pending legal proceedings and related matters  please see note  commitments and contingencies  of the notes to consolidated financial statements on page ii acquisitions and dispositions for information on the company s acquisitions and dispositions of businesses  please see note of the notes to consolidated financial statements on page ii recently issued accounting standards in the fourth quarter of  the company adopted financial accounting standard fas which requires the presentation of both basic and diluted earnings per share 
basic earnings per share as calculated in accordance with fas does not differ from earnings per share reported in prior periods and diluted earnings per share is not materially different from basic earnings per share 
in june  the financial accounting standards board issued statement no 
 reporting comprehensive income  which establishes standards for reporting comprehensive income and its components  and statement no 
 disclosures about segments of an enterprise and related information  which establishes revised reporting and disclosure requirement for operating segments 
the company will adopt statement nos 
and by year end these statements increase disclosure only and will have no effect on the company s financial position or results of operations 
cautionary statement regarding forward looking information certain statements contained herein or in other company documents and certain statements that may be made by management of the company orally  including statements regarding cost savings from manufacturing restructuring  may contain forward looking statements as defined in the private securities litigation reform act of because actual results are affected by risks and uncertainties  the company cautions investors that actual results may differ materially from those expressed or implied 
factors which could cause the actual results to differ materially from expected and historical results include  but are not limited to health care industry consolidation resulting in customer demands for price concessions  competitor s attempts to gain market share through aggressive marketing programs  fewer medical procedures performed in a cost conscious environment  the lengthy approval time by the fda or other government authorities to clear medical devices for commercial release  unanticipated product failures  legislative or administrative reforms to the us medicare and medicaid systems or other non us reimbursement systems in a manner that would significantly reduce reimbursements for procedures using the ii cautionary statement regarding forward looking information continued company s medical devices  the acquisition of key patents by competitors that would have the effect of excluding the company from new market segments  the uncertainty of whether increased research and development expenditures will result in increased sales  unpredictability of existing and future litigation including litigation regarding product liability  uncertainty related to tax appeals and litigation  price increases from the company s suppliers of critical components  foreign currency fluctuations  unanticipated business disruptions from year issues  the risk that the company may not achieve manufacturing or administrative efficiencies as a result of the company s recent restructuring or in the integration of recently acquired businesses 
ii 
